{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Theravance Biopharma, Inc.
Theravance Biopharma Hits Day Low of $13.08 Amid Price Pressure
Theravance Biopharma, Inc. faced notable stock volatility, dropping significantly during trading. Despite a strong yearly performance with a 52.57% increase, recent struggles are evident with a year-to-date decline. The company reported an 18.51% rise in net sales and has high institutional holdings, indicating robust investor confidence.
Theravance Biopharma Faces Weak Start with 24.7% Gap Down Amid Market Concerns
Theravance Biopharma, Inc. opened with a notable loss, contrasting with the S&P 500's modest decline. Over the past month, the company has underperformed the index significantly. Its market capitalization is around USD 996 million, with a price-to-earnings ratio of 49.00 and a unique financial structure.
Theravance Biopharma Experiences Valuation Adjustment Amid Strong Performance Metrics
Theravance Biopharma, Inc. has recently adjusted its valuation, currently exhibiting a high P/E ratio of 49 and a price-to-book value of 3.21. The company has achieved impressive stock returns of 112.49% over the past year, significantly outperforming the S&P 500, and has shown strong performance relative to its peers.
Theravance Biopharma, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Resilience
Theravance Biopharma, Inc. has recently revised its evaluation amid current market dynamics. The company’s stock price is slightly down, yet it has achieved a remarkable 99.38% return over the past year, significantly outperforming the S&P 500. Technical indicators present a mixed outlook, reflecting ongoing market resilience.
Theravance Biopharma Hits New 52-Week High of $18.96, Up 112.64%
Theravance Biopharma, Inc. achieved a new 52-week high of USD 18.96, reflecting strong performance in the pharmaceuticals sector. The company reported a 112.64% increase in stock performance over the past year and an 83.75% rise in net sales, supported by high institutional holdings and solid financial metrics.
Theravance Biopharma Achieves Multibagger Status with 103.74% Stock Surge Over Past Year
Theravance Biopharma, Inc. has recently undergone a revision in its score, reflecting its impressive performance metrics and strong market position. The stock has outperformed the S&P 500 significantly over the past year and reported substantial growth in net sales and operating cash flow, indicating robust operational strength.
Is Theravance Biopharma, Inc. technically bullish or bearish?
As of October 31, 2025, Theravance Biopharma, Inc. shows a bullish technical trend with strong MACD and Bollinger Bands indicators, despite mixed signals from RSI and KST, and has significantly outperformed the S&P 500 year-to-date and over the past year.
Theravance Biopharma Hits New 52-Week High of $15.34, Up 74.94%
Theravance Biopharma, Inc. achieved a new 52-week high of USD 15.34 on November 3, 2025, reflecting strong performance in the pharmaceuticals sector. The company reported significant growth in net sales and operating cash flow, alongside high institutional holdings, indicating robust operational fundamentals and a positive recovery trajectory.
Is Theravance Biopharma, Inc. technically bullish or bearish?
As of October 31, 2025, Theravance Biopharma, Inc. shows a bullish trend supported by positive MACD and Bollinger Bands, despite mixed signals from the RSI and KST, and has significantly outperformed the S&P 500 with an 84.71% return over the past year.
Is Theravance Biopharma, Inc. technically bullish or bearish?
As of October 31, 2025, Theravance Biopharma, Inc. shows a bullish trend supported by daily moving averages and positive indicators, despite some mixed signals from MACD and RSI, while outperforming the S&P 500 over the past year with a return of 77.91%.
Is Theravance Biopharma, Inc. technically bullish or bearish?
As of October 31, 2025, Theravance Biopharma, Inc. shows a bullish trend supported by moving averages and Bollinger Bands, despite mixed signals from MACD and RSI, while significantly outperforming the S&P 500 year-to-date and over the past year, but lagging in longer-term returns.
Is Theravance Biopharma, Inc. technically bullish or bearish?
As of October 24, 2025, Theravance Biopharma, Inc. shows a bullish trend supported by strong indicators like MACD and moving averages, though caution is advised due to a bearish RSI on the monthly chart and mixed volume trends.
Is Theravance Biopharma, Inc. technically bullish or bearish?
As of October 24, 2025, Theravance Biopharma, Inc. shows a bullish trend supported by strong MACD and KST indicators, although caution is advised due to a bearish RSI signal.
Is Theravance Biopharma, Inc. technically bullish or bearish?
As of October 24, 2025, Theravance Biopharma, Inc. shows a bullish trend supported by strong MACD and KST indicators, despite a bearish monthly RSI, with a year-to-date return of 51.75% outpacing the S&P 500's 15.47%.
Is Theravance Biopharma, Inc. overvalued or undervalued?
As of October 17, 2025, Theravance Biopharma, Inc. is considered overvalued with a valuation grade shift from attractive to expensive, reflected in its high Price to Book Value of 3.39 and P/E ratio of 48.04, despite significant losses and negative returns on capital and equity.
Theravance Biopharma, Inc. Experiences Revision in Its Stock Evaluation Amid Market Challenges
Theravance Biopharma, Inc. has faced significant operational challenges, reflected in its negative financial metrics, including a loss-making P/E ratio and negative returns on capital and equity. Despite these hurdles, the company has achieved a notable year-to-date stock performance, outperforming the broader market.
Is Theravance Biopharma, Inc. overvalued or undervalued?
As of October 17, 2025, Theravance Biopharma, Inc. is considered overvalued with a high P/E ratio of 48.04 and significant financial challenges, despite a strong year-to-date return of 51.54%.
Is Theravance Biopharma, Inc. overvalued or undervalued?
As of October 17, 2025, Theravance Biopharma, Inc. is considered overvalued with a valuation grade shift from attractive to expensive, indicated by high financial metrics compared to peers, despite strong recent returns.
Theravance Biopharma Hits New 52-Week High of $15.15, Up 67.59%
Theravance Biopharma, Inc. achieved a new 52-week high of USD 15.15 on October 6, 2025, reflecting strong performance in the pharmaceuticals sector. The company reported an 83.75% increase in net sales and a 67.59% rise in stock value over the past year, showcasing robust operational capabilities.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
